Rives Consult Welcomes Naz Yacobi as Director of Regulatory Affairs

Winston-Salem, NC – September 15, 2025 – Rives Consult, a U.S.-based consultancy specializing in helping international medical device companies navigate FDA regulatory, QMS, reimbursement, and commercialization pathways, is pleased to announce the appointment of Naz Yacobi as Director of Regulatory Affairs.

Naz brings deep expertise in regulatory affairs and quality assurance, with extensive experience supporting early-stage medical device and health-tech companies. Her appointment underscores Rives Consult’s commitment to delivering execution-focused regulatory and quality strategies that help overseas innovators succeed in the U.S. market.

“Naz’s background in regulatory affairs and quality systems strengthens the foundation of our work with clients,” said Rives Bird, President of Rives Consult. “Her leadership and hands-on approach align perfectly with our mission of acting as an extension of our clients’ teams—getting the work done, not just advising.”

Naz has worked across multiple sectors of the medical device industry, including IVD and combination products. Her strengths in FDA regulatory strategy, submission, labeling, and QMS execution (under CFR 820) align directly with Rives Consult’s model of serving as a fractional U.S.-based workforce partner rather than a traditional advisory firm.

About Rives Consult

Rives Consult is a boutique consultancy based in Winston-Salem, NC, dedicated exclusively to the medical device and health technology sectors. Unlike traditional advisory firms, Rives Consult integrates directly with client teams as an extension of their workforce, providing execution-focused support across regulatory strategy (FDA pre-subs, labeling, QMS under CFR 820), reimbursement strategy (CPT, LCV/CAC), and U.S. commercialization. The firm specializes in guiding overseas and early-stage companies through the complexities of entering and succeeding in the U.S. healthcare market.

For more information, visit www.rivesconsult.com.